Briefing Material
for 3rd quarter ended Sep. 30, 2025
Nov. 6, 2025
NAKANISHI INC.
Disclaimer
The information presented in these materials contains forward-looking statements about future
business performance. These statements by definition involve risks and uncertainties and are not intended to guarantee future performance. Actual results in the future may differ from expectations and the projections presented in these materials due to changes in the global economy and fluctuations in foreign currency exchange rates and so on.
© 2025 NAKANISHI INC.
Product Lineup
Dental Business
Development, production and sales of wide range of dental equipment, which cover such as restorative dentistry, periodontics, oral surgery, mobile dental care, etc.
Handpiece Implant motor Oral hygiene system Clinical micro motor
DCI Business
Presenting results of DCI, the U.S. dental chair manufacturer, acquired in 2023, as an independent segment.
Development, production and sales of dental chairs and related equipment for the North American market.
Dental chair
Dental cabinet
Dental parts
Surgical Business
Development, production and sales of bone grinding and cutting drills which can be used in areas of neurosurgery, spine surgery and orthopedic surgery.
Console Surgical motor Attachment Bur
Industrial Business
Development, production and sales of spindles which can be used in high-precision processes in wide range of industrial areas such as automobile and precision parts industries.
Controller & Spindle
Controller & Spindle
Electric hand grinder
Ultrasonic cutter
Performance Highlights
N
et sales were in line with the plan. Surgical segment maintained a high growth rate,
Dental and DCI segments remained solid, and Industrial segment returned to revenue growth, resulting in a consolidated net sales increase of +3.8% YoY.
The impact of U.S. tariff policies became evident in Q3. Although the profitability of DCI segment has declined, it remains within expectations. EBITDA decreased YoY, but it
exceeded the plan.
Although there are some positive signs, such as reductions in U.S. tariffs on China, the outlook for U.S. demand remains uncertain. The full-year forecast announced on May
12 remains unchanged.
Consolidated P/L
M of JPY | FY2025Q3 | FY2024Q3 | Forecast | ||||||
Actual | Actual | Ratio | (As of May 12) | Ratio | |||||
Net sales | 58,752 | 56,621 | +3.8% | 58,311 | +0.8% | ||||
Gross Profit | 33,541 | 32,924 | +1.9% | 32,103 | +4.5% | ||||
Ratio to net sales | 57.1% | 58.1% | - | 55.1% | - | ||||
EBITDA ＊ | 14,786 | 15,597 | -5.2% | 12,983 | +13.9% | ||||
Margin | 25.2% | 27.5% | - | 22.3% | - | ||||
Operating Profit | 10,540 | 11,392 | -7.5% | 8,646 | +21.9% | ||||
Ratio to net sales | 17.9% | 20.1% | - | 14.8% | - | ||||
Ordinary Profit | 10,934 | 12,280 | -11.0% | 9,240 | +18.3% | ||||
Ratio to net sales | 18.6% | 21.7% | - | 15.8% | - | ||||
Profit attributable to | 6,181 | 8,079 | -23.5% | 5,048 | +22.4％ | ||||
Ratio to net sales | 10.5% | 14.3% | - | 8.7% | - | ||||
E | P | S | (JPY) | 73.85 | 95.42 | - | - | - | |
＊ EBITDA = Operating profit + Depreciation + Amortization | |||||||||
Currency rate | - Against the US dollar (JPY) | 148.82 | 150.61 | -1.79 | 145.00 | +3.82 | |||
- Against the EURO | (JPY) | 165.51 | 163.86 | +1.65 | 155.00 | +10.51 | |||
Forex impact: Net sales -404M of JPY (vs FY2024Q3 Actual), +1,649M of JPY (vs FY2025 Forecast)
Change in Net Sales by Business Segment
M of JPY
+2,130
+3.8%
+125
Industrial
+2.5%
58,752
56,621
DCI
+2.7%
Surgical
+30.0%
Dental
+1.9%
+658
+386
+960
FY2024Q3 Actual A | FY2025Q3 Actual B | of which: forex impact | Change B/A-1 | |
Dental | 34,126 | 34,784 | -230 | +1.9% |
DCI | 14,305 | 14,692 | -170 | +2.7% |
Surgical | 3,207 | 4,168 | -9 | +30.0% |
Industrial | 4,982 | 5,107 | +5 | +2.5% |
Total | 56,621 | 58,752 | -404 | +3.8% |
FY2024Q3
Net sales
FY2025Q3
Net sales